argenx Receives Positive CHMP Opinion for Efgartigimod for the Treatment of Adult Patients with Generalized Myasthenia Gravis in EuropeGlobeNewsWire • 06/24/22
argenx Announces the UK MHRA has Granted Early Access to Efgartigimod for Generalized Myasthenia GravisGlobeNewsWire • 05/31/22
argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering DiseasesGlobeNewsWire • 05/19/22
argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term GainSeeking Alpha • 05/18/22
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/07/22
argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune ThrombocytopeniaGlobeNewsWire • 05/05/22
argenx Reports First Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 05/05/22
argenx to Report First Quarter 2022 Financial Results and Business Update on May 5, 2022GlobeNewsWire • 04/28/22
argenx Presents Interim Results from ADAPT+ Open-Label Extension Study Evaluating VYVGART® (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis at 2022 AAN Annual MeetingGlobeNewsWire • 04/05/22
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual MeetingBusiness Wire • 04/01/22
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On ArgenxBenzinga • 03/22/22
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular DisorderBenzinga • 03/22/22
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia GravisBusiness Wire • 03/22/22
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business UpdateGlobeNewsWire • 03/03/22
argenx to Report Full Year 2021 Financial Results and Fourth Quarter Business Update on March 3, 2022GlobeNewsWire • 02/24/22